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Introduction: Helicobacter pylori strains expressing cytotoxic CagA protein are more commonly 
associated with peptic ulceration, atrophic gastritis and gastric adenocarcinoma than those lacking 
CagA. Determination of anti-CagA antibodies, therefore, acquires a relevant clinical significance in the 
serological detection of H. pylori infection and disease risk prediction. However, the CagA-serology 
has been questioned due to the differences found in their performance evaluations in different 
populations. 
Objective: To obtain a recombinant CagA fragment useful for serodiagnosis of H. pylori infection
Methods: A fragment of the cagA gene was cloned into a prokaryotic T7 RNA polymerase expression 
vector. A recombinant C-terminal His6-tagged CagA was expressed, subsequently solubilized with urea 
and purified by immobilized metal affinity chromatography. The performance of the recombinant protein 
was evaluated using 180 human serum samples with an in-house Western blot assay compared to the 
Helicoblot 2.1 reference test.  
Results: The expressed His6-tagged CagA showed an immunoreactive 80kDa band as was revealed 
by SDS-PAGE and Western blot analysis using two different specific anti-CagA polyclonal antibodies. 
The recombinant protein was successfully purified obtaining a 93% of purity. The performance analysis 
of the purified recombinant antigen showed good immunoreactivity and exhibited values of sensitivity, 
specificity and accuracy of 88.1%, 100% and 92.7%, respectively. 
Conclusion: The CagA fragment of the study may constitute a useful tool for serological diagnosis of 
CagA-positive H. pylori infection.
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Clonación y expresión de un fragmento recombinante del gen cagA de Helicobacter pylori y su 
evaluación preliminar en el serodiagnóstico
Introducción. Las cepas de Helicobacter pylori que expresan la citotoxina CagA, se asocian más 
frecuentemente con úlcera péptica, gastritis atrófica y adenocarcinoma gástrico que las que carecen 
de esta citotoxina. Por lo anterior, el determinar la presencia de anticuerpos anti-CagA adquiere gran 
importancia clínica en la detección serológica de la infección por H. pylori y la predicción del riesgo 
de enfermedades. Sin embargo, los métodos serológicos que emplean CagA han sido cuestionados 
debido a las diferencias encontradas en las evaluaciones de su desempeño en diversas poblaciones.
Objetivo. Obtener un fragmento recombinante de la proteína CagA para el serodiagnóstico de la 
infección por H. pylori.
Materiales y métodos. Un fragmento del gen cagA fue clonado en un vector de expresión procariota 
que contenía el promotor de la T7 ARN polimerasa. El fragmento de la proteína CagA con seis histidinas 
en la región C-terminal, se expresó, se solubilizó con urea y se purificó por cromatografía de afinidad 
con iones metálicos inmovilizados. El desempeño de la proteína recombinante se evaluó empleando 
un método in house de Western Blot y 180 sueros humanos. Los resultados se compararon con la 
prueba de referencia Helicoblot 2.1.
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Resultados. La proteína CagA expresada mostró una banda inmunorreactiva de 80 kDa en el Western 
Blot al emplear dos anticuerpos policlonales anti-CagA específicos. La proteína recombinante fue 
purificada hasta un 93 % de pureza y el análisis de desempeño del antígeno recombinante purificado 
mostró buena inmunorreacción y exhibió valores de sensibilidad, especificidad y exactitud de 88,1 %, 
100 % y 92,7 %, respectivamente.
Conclusiones. El fragmento de la proteína CagA del estudio puede constituir una herramienta útil para 
el diagnóstico serológico de la infección por cepas de H. pylori positivas para CagA. 
Palabras clave: Helicobacter pylori, pruebas serológicas. 
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Helicobacter pylori is a Gram-negative spiral-
shaped bacterium that persistently colonizes the 
stomach of more than half of the human population. 
This persistent colonization plays an important role 
in the appearance of gastroduodenal pathologies, 
such as peptic ulcers, gastric adenocarcinoma and 
gastric mucosa-associated lymphoid tissue (MALT) 
lymphoma (1).
The persistence of this infection, which is crucial 
for developing chronic disease phenotypes, 
mainly depends on specific characteristics of the 
bacterium. The most important virulence factor of 
H. pylori is the cytotoxin-associated antigen CagA. 
This protein is coded by the cagA gene that is part 
of the cag-pathogenicity island which encodes 
the components of a type IV secretion system 
(T4SS). H. pylori uses this T4SS to inject CagA into 
human gastric cells, where it perturbs several host 
signaling pathways to provide a local environment 
that is more suitable for the pathogen survival 
and thereby promoting severe damages of gastric 
epithelial cells and mucosa (2,3,4).
The CagA protein is an immunodominant antigen 
(5,6) and the cagA-positive strains are commonly 
associated with more severe gastroduodenal 
diseases than cagA-negative strains (7,8). Several 
studies in cell culture and animal models indicate 
the likely role of CagA in human cancer associated 
with H. pylori infection (3). Transgenic expression 
of CagA in mice led to the development of gastric 
epithelial hyperplasia and adenocarcinoma of the 
stomach and the small intestine, providing the first 
direct evidence of the potential oncogenicity of 
CagA in vivo (9). Thus, CagA is the first bacterial 
oncoprotein to be identified in relation to human 
cancer. Therefore, determination of the CagA-
status in H. pylori infection is an important and an 
informative approach in disease risk prediction.
Different methods have been used to detect H. 
pylori infection with CagA-positive strains. Among 
all, the serologic methods have been successfully 
used due to the immunogenicity of this protein and 
the non- invasivity of the method (10). In addition, 
it has been observed that CagA seropositivity is 
able to predict the development of atrophy and 
constitute a risk factor for intestinal metaplasia 
(11). However, the accuracy of CagA-serology has 
been challenged due to the differences found in 
their evaluations. It has been suggested that this 
variability is mainly related with the differences 
in the antigens or methodologies used to detect 
the anti-CagA antibodies, or the use of different 
populations (12). Here we described a new 
recombinant fragment of CagA and evaluated its 




Serum samples were obtained from 180 consecutive 
Cuban dyspeptic patients with an average age 
of 36.5 years (range, 18 to 55) who attended the 
Department of Gastroenterology of Carlos J. Finlay 
Hospital.  Ninety-two of the patients presented 
gastritis (51.1 %), 34 gastric ulcer (18.8 %) and 
54 duodenal ulcer (30.1 %). All patients gave their 
written informed consent to participate in the study 
and the Carlos J. Finlay Hospital ethic committee 
approved the protocol by which the specimens 
were obtained.
Bacterial strains, plasmids and reagents
H. pylori strain 26695 was used for genomic DNA 
extraction. E. coli Mach1 (Invitrogen, USA) was 
used as a host strain for cloning manipulation of 
cagA gene. E. coli BL21(DE3) (Invitrogen, USA) was 
used as CagA expression strain. The pET22b(+) 
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plasmid (Novagen, USA) was used as cloning 
and expression vector. This vector contains the T7 
promoter and allows expression of the recombinant 
protein fused to histidine tail at the C-terminus. The 
restriction enzymes and PCR reagents used in 
cloning procedures were purchased from Roche, 
USA.
Molecular techniques and construction of the 
expression plasmid
Genomic DNA from H. pylori was extracted by 
CTAB methodology with phenol/chloroform and 
isopropanol precipitation as previously described 
(13). A fragment of the cagA gene was amplified by 
PCR using forward primer cagA.F [5’-CATGCCA
TGGGGGATAACAGGCAAGCTTTTGA-3’] which 
created the NcoI site (nderlined), and reverse primer 
cagA.R [5’-GAATTCTCGAGGTCGCTTTTTGC-3’] 
XhoI site These primers were designed based on 
the DNA sequences of 26695 cagA gene obtained 
from the GenBank database and using the Gene 
Runner software version 3.05.
PCR reactions were performed in final volumes of 50 
μl containing 100 ng of H. pylori genomic DNA, 0.2 
mM dNTP, 2.5 mM MgCl2, 0.6 μM of each primer, 1 
unit of Taq DNA polymerase and 1× reaction buffer. 
For amplification, a Thermal Cycler, Mastercycler® 
personal (Eppendorf, Germany) was used with the 
following settings: 1 min at 94 °C followed by 40 
cycles of 1 min at 94 ºC, 1 min at 61 °C and 1 min at 
72 °C and then a final extension of 5 min at 72 °C. 
The PCR products were analyzed by agarose (2%) 
gel electrophoresis using a 100 bp DNA molecular 
size marker (Roche, USA) and then purified using 
the High Pure PCR Product Purification Kit (Roche, 
USA).
The purified PCR product was cloned into the 
pET22b(+) expression vector following the 
manufacturer instructions. The cloning product was 
transformed into E. coli Mach1 electrocompetent 
cells and recombinant clones were identified by 
plasmid purification using the High Pure Plasmid 
Isolation Kit (Roche, USA) and confirmed by 
restriction enzyme analysis. The identity of the insert 
was determined by DNA sequencing (Macrogen 
Inc., Korea). Sequencing reactions were performed 
for both DNA strands, and the ClustalW2 multiple-
sequence alignment software was used to analyze 
sequencing results.
Expression and localization of recombinant CagA
Recombinant plasmid pET22b(+)-CagA was 
transformed into E. coli BL21(DE3) electrocompetent 
cells and recombinant clones were identified as 
described above. One recombinant clone was 
used to inoculate 5 ml of Luria–Bertani medium 
containing 100 μg/mL ampicillin which was 
incubated in an orbital shaker (37 ºC, 200 rpm) 
until OD600nm 0.6. At this moment, expression of the 
recombinant protein was induced with isopropyl-
b-D-1-thiogalactopyranoside (IPTG), with a final 
concentration of 0.1 mM, and incubated for 
additional 4 h in the same conditions. Cells were 
harvested by centrifugation (10 000 g, 4 °C, 5 min) 
and resuspended in 0.1 M phosphate-buffered 
saline, pH 7.4 (PBS) and later the 5× SDS-PAGE 
loading buffer was added (250 mM Tris–HCl pH 
6.8, 50% glycerol, 1 M 2-mercaptoethanol and 
1% SDS). After boiling for 10 min, the sample 
was submitted to 12% SDS-PAGE according to 
Laemmli (14). Expression of the recombinant 
protein was visualized by Coomassie Blue staining. 
To confirm the presence and immunorreactivity of 
the recombinant protein, Western blot analysis was 
carried out essentially as Towbin and Gordon (15) 
and two different anti-CagA polyclonal antibodies, 
kindly provided by professors Guillermo Pérez-
Pérez (New York University, School of Medicine, 
New York, USA) and Rainer Haas (Ludwig 
Maximilian University, Munich, Germany), were 
used.
In order to improve the CagA expression, several 
experimental parameters were optimized: 
temperature, IPTG concentration, OD600nm at 
induction, and incubation time after induction. This 
protein expression analysis was monitored by SDS-
PAGE and using a Gene Genius gel documentation 
system (Syngene, UK).
To localize the recombinant CagA protein (rCagA) 
into the cell extract, the clone expressing the rCagA 
was tested regarding the solubility of the protein. 
Cells were lysed by freeze-thawed three times 
in buffer A (20 mM Tris, pH 7, containing 0.5 M 
NaCl, 5 mM imidazole, and 1 mM PMSF) at a ratio 
of 1 g of wet cells/5 ml of buffer A, as previously 
described (16). The soluble and insoluble fractions 
were separated by centrifugation at 10 000 g for 5 
min at 4 °C and applied in a 12% SDS–PAGE as 
above.
Purification of recombinant CagA
The cell lysis insoluble fraction, containing the 
rCagA, was suspended in buffer A and treated 
with different concentrations of Urea (2, 4, 6, and 
8 M) employing an Ultra-Turrax homogenizer 
(IKA-WERKE, Germany) at 9500 rpm for 1min. 
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After incubation overnight in gentle agitation at 
4 °C, the samples were centrifuged at 14 000 g 
for 20 min at 4 °C and all soluble and insoluble 
fractions were analyzed by 12% SDS–PAGE 
to determine the minimal Urea concentration 
needed for the best rCagA solubilization. Then, the 
recombinant protein was purified by immobilized 
metal affinity chromatography (IMAC) using a 
Quelating Sepharose Fast Flow matrix (Amersham 
Pharmacia, Sweden) pre-charged with Cu2+. The 
column was equilibrated with buffer A containing 4 
M Urea and the protein refolding was performed on-
column using a linear gradient from 4 to 0 M Urea in 
buffer A. The recombinant protein was eluted with 
a linear gradient from 5 to 200 mM imidazole and 
fractions of 1 ml were collected and analyzed by 
12% SDS–PAGE. The purified protein was dialyzed 
on Sephadex G-25 column equilibrated with PBS.
Determination of protein concentration and purity
The concentration and purity of the rCagA was 
determined by Bradford’s assay (17) and SDS-
PAGE analysis using the Syngene Gene Genius 
imaging system, UK, respectively. Bovine serum 
albumin was used as standards in both cases.
Evaluation of recombinant CagA antigen for 
serodiagnosis
In order to assess the efficacy of the rCagA in 
serodiagnostic, a panel of 180 human sera was 
simultaneously evaluated using an in-house Western 
blot assay and the commercial immunoblot assay 
Helicoblot 2.1 (HB 2.1) (Genelabs Diagnostics, 
Singapore), which was regarded as the reference 
assay in the study. The Western-rCagA was 
performed as follow: the proteins resolved on a 12% 
SDS-PAGE gel were transferred to nitrocellulose 
membrane (Amersham Pharmacia, Sweden) for 3 
h at 36V using a wet tank transfer system (Hoefer 
Inc., USA). The membranes were incubated with 
blocking reagent (5% skim milk in PBS), 1h at 4°C 
and subsequently incubated with the serum samples 
overnight in gentle agitation at room temperature. 
All sera were diluted 1/100 in PBS containing 
0.05% Tween 20. After washing with distilled water 
containing 0.05% Tween 20, membranes were 
incubated 1 h at room temperature with a specific 
anti-human immunoglobulin antibody conjugated 
to horseradish peroxidase (Promega, USA) diluted 
1/5000 in PBS containing 1% skim milk and 0.05% 
Tween 20. Reacting bands were detected using 
3,3´-diaminobenzidine substrate 0.02% in buffer 
10mM Tris, pH 7.6.
The HB 2.1 assay was developed in accordance 
with the manufacturer’s instructions. Results from 
Western-rCagA test were compared with those 
from the HB 2.1 test to assess the performance of 
the recombinant antigen by determining the relative 
sensitivity, specificity and accuracy as described 
below,
Sensitivity = a / (a + c) x 100, where ‘a’ is the number 
of sera positive by both, the Western-rCagA and 
HB 2.1 while ‘c’ is the number of sera positive by 
HB 2.1 but negative by Western-rCagA.
Specificity = d / (b + d) x 100 where ‘d’ is the number 
of sera negative by both, the Western-rCagA and 
HB 2.1 while ‘d’ is the number of sera negative by 
HB 2.1 but positive by Western-rCagA.
Accuracy = (a + d) / (a + b + c + d) x 100.
Results
Cloning of H. pylori CagA gene
The designed primers allowed effective amplification 
of the selected fragment of cagA gene. These PCR 
reactions generated DNA fragments of 2130 bp 
as it was expected. Amplified fragment digested 
with NcoI and XhoI, was purified and successfully 
cloned into the pET22b(+) expression vector as was 
corroborated by restriction enzyme analysis (Fig. 
1). Sequencing of the pET22b(+) insert, compared 
to 26695 cagA gene, obtained from the GenBank 
database, confirmed the identity of the cloned cagA 
sequence (data not shown).
Expression of recombinant CagA
E. coli BL21(DE3) harbouring plasmid pET22b(+)-
CagA, expressed a major protein of approximately 
80kDa upon IPTG induction that could be detected 
by SDS–PAGE analysis (Fig. 2A, lane 5). This 
molecular size corresponds to the estimated 
molecular weight of the selected cagA fragment 
(81.5kDa). After SDS-PAGE analysis, the target 
protein was further analyzed by immunoblotting 
with two different anti-CagA polyclonal antibodies 
to corroborate the presence of the recombinant 
protein. The Western blot assay also showed a 
major reacting band of 80kDa approximately (Fig. 
2B, lane 1). This band was not detected without 
IPTG induction (Fig. 2B, lane 2).
The optimization of the recombinant protein 
production showed that the best conditions were 
an expression at a OD600nm 0.8 with 1mM IPTG 
at 37°C and 200 rpm during 4 h. The expressed 
protein under these conditions constituted 27% 
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of the total cellular protein as was determined by 
densitometry. The cells were successfully broken 
by the freeze-thaw procedure and the rCagA was 
found in the insoluble fraction after cell lysis (data 
not shown).
Purification of recombinant CagA
The recombinant protein accumulated in the 
insoluble fraction of cell lysate was solubilized in 
buffer containing urea. The solubilization assays 
allowed determining that 4 M urea was the minimal 
concentration needed to suspend the rCagA with 
the minimum presence of contaminants (data not 
shown).
The recombinant protein was successfully purified 
by IMAC and the rCagA was eluted from the column 
at 30 mM of imidazole with approximately 93% 
purity (Fig. 2D, lane 3).
Performance of the Western-rCagA
The performance of the rCagA in serodiagnostic 
was studied using a panel of 180 serum samples 
and the HB 2.1 as the reference test. Among all 
sera tested, the HB 2.1 identified 109 (60.6%) CagA 
positive and 71 (39.4%) CagA negative cases. On 
the other hand, 96 from the 109 CagA positive sera 
detected by HB 2.1 were also immunorreactive 
with the rCagA, while all the 71 CagA negative 
cases detected by HB 2.1 were also negative by 
the Western-rCagA. Thus, there were 13 false 
Figure 1. Agarose gel analysis of the cagA fragment cloning. 
Lane 1, pET22b(+) cloning vector digested with NcoI. Lane 2, 
pET22b(+)-cagA recombinant vector digested with NcoI and 
XhoI. Lane 3, PCR cagA gene product (2130bp). Lane 4, the 
recombinant vector pET22b(+)-cagA linearized with XhoI. Lane 
5, DNA weight marker 1000bp (Roche, USA). DNA band sizes 
are in base pairs (bp)
Figure 2. Expression and purification of the CagA recombinant protein. Panel A. 12% SDS-PAGE analysis of the expressed CagA 
protein. Lane 1, Protein weight marker (Promega, USA). Lane 2, E. coli BL21 DE3 transformed with the recombinant pET22B(+)-Cag 
plasmid without IPTG induction. Lane 3, E. coli BL21 DE3 transformed cells with the non expressing pET22b(+) vector. Lane 4, E. 
coli BL21 DE3 transformed cells with the recombinant pET22b(+)-CagA plasmid without IPTG induction. Lane 5, E. coli BL21 DE3 
transformed cells with the recombinant pET22b(+)-CagA induced with 0.1 mM IPTG. Panel B and C. Western blot analysis of the 
recombinant CagA with two different polyclonal anti-CagA antibodies. Lane 1, E. coli BL21 DE3 transformed with the recombinant 
pET22b(+)-CagA plasmid with IPTG induction. Lane 2, Transformed BL21 DE3 cells induced without IPTG. Panel D. 12% SDS-
PAGE analysis of the recombinant CagA purification. Lane 1, total cell protein extract of the BL21 DE3 with pET22b(+)-CagA. Lane 
2, flowthrough of the IMAC column. Lane 3, recombinant CagA protein eluted with 30 mM Imidazole. Protein band sizes are in 
kilodalton (kDa).
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negative and none false positive results when 
the Western-rCagA was used to detect anti-CagA 
antibodies. Therefore, the Western blot assay using 
the rCagA developed here showed a sensitivity, 
specificity, and accuracy of 88.1%, 100%, and 
92.7%, respectively.
Discussion
Several studies using diagnostic methods to detect 
CagA antibodies have demonstrated that this 
antigen improve the sensitivity of H. pylori detection 
(18).  Also, it has been observed that the positivity 
for CagA antibodies has the ability to predict the 
development of atrophy and appears related with 
young gastric cancer cases (10). However, the 
accuracy of the tests developed with this regard 
has been questioned because the results differed 
when they were used in different populations. It 
has been suggested that an important issue to this 
heterogeneity appeared to result from differences 
in the antigens used to detect anti-CagA antibodies 
(12). Consequently, new studies using the already 
existent CagA antigens, and/or some new design 
fragments of the cytotoxin, should be done to 
evaluate the reactivity of representative populations 
to different antigens.
In the present study a new recombinant fragment of 
CagA cytotoxin was expressed in E. coli. The goal 
of the study has been the production of a specific 
antigen that should be able to react with a broad 
range of human anti-CagA antibodies and could 
improve the serodiagnosis of the CagA-positive H. 
pylori infection.
The selected fragment corresponds to all conserved 
N-terminal and central conserved regions of the 
CagA protein, containing 716 aa and an estimated 
molecular size of 81.5 kDa. Previous studies have 
demonstrated that CagA is a challenging protein 
for recombinant expression, due to a propensity 
for degradation (6,19). Specifically, it has been 
suggested that the region preceding the first EPIYA 
motif contains an important cleavage site (19). 
We designed a region that excluded both, this site 
and the CagA variable region at the C-terminus 
(the EPIYA region) and also lacked the most 
proximal N- terminal variable region. The selected 
CagA sequence constitutes a suitable fragment 
for the recognition of antibodies due to contain 
several epitopes that are highly conserved and 
immunogenic (20,21). In agreement with the above 
data, the selected recombinant CagA fragment of 
this study showed a low degree of degradation and 
was highly immunoreactive (Fig. 2 and 3).
For large-scale production of recombinant proteins, 
the T7-Lac promoter based vectors containing 
histidine tails have been successfully used for 
hyper-expression of the selected proteins, which 
help in devising simple chromatography protocols 
for obtaining highly pure protein in high yields (22). 
The expression system used in this study produced 
a large amount of the heterologous protein (27% of 
the total cellular protein). The rCagA was expressed 
as C-terminally His6-tagged protein and was 
purified by IMAC. The use of the histidine affinity 
tag facilitated the recovery of the recombinant 
protein, using one-step chromatography procedure, 
to obtain a 93% of purity (Fig. 2, panel D) without 
affecting its immunoreactive properties (Fig. 3, 
panel A).
The two polyclonal anti-CagA antibodies used here 
were generated using two different recombinant 
CagA fragments (20,23). These two recombinant 
proteins comprise different fragments, which are 
mostly included in the wide conserved sequence 
selected for our rCagA. Therefore, the good reactivity 
observed with both antibodies demonstrated the 
identity of the CagA produced fragment (Fig. 2, 
panel B and C).
The CagA seropositivity (60.6%) obtained with 
Helicoblot 2.1 test in this study was similar to the 
positivity observed in CagA genotyping of Western 
strains (24) and slightly lower than the cagA positive 
strains detected in Cuban H. pylori isolates (25). 
The Western blot assay with the rCagA developed 
here demonstrated adequate performance in 
comparison to HB 2.1 that contains the entire 
CagA antigen. This comparison showed sensitivity 
of 88.1%, specificity of 100% and accuracy of 
92.7%. The sensitivity was the lowest performance 
parameter observed, but it is in the accepted range 
compared with others ELISA and immunoblotting 
tests developed to detect CagA antibodies 
(26,27). Interesting, among the 13 false negative 
samples obtained with the Western-rCagA, 9 were 
classified as H. pylori negative CagA positive by 
HB 2.1. It is though that CagA seropositivity in H. 
pylori-seronegative subjects may either be a sign 
of a past H. pylori infection due to the long life of 
anti-CagA antibodies (18,28) or represent a false 
positive reaction (29). Therefore, probably the 
rCagA of this study may not contain the epitopes 
causing either of the above mentioned events that 
should be, if demonstrated, an advantage of this 
recombinant fragment to diagnose CagA-positive 
H. pylori infection. In addition, our rCagA should 
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be sensitive enough due to the fact that contains 
the conserved part of the CagA cytotoxin, which 
has been recently shown to have the most reactive 
epitopes of the entire CagA protein (21). On the 
other hand, there were no false positive results 
and therefore the Western-rCagA showed 100% 
specificity. This is also a good result for the rCagA 
of this study because the lack of specificity of anti-
CagA tests has been attributed in part to differences 
in the CagA antigens used (12,30).
Taken together, the data of this study suggest 
that the recombinant CagA fragment developed 
here should be a good reagent to be included in a 
CagA serodiagnostic assay to be standardized and 
validated in representative populations.
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